Vumerity (diroximel fumarate)
- Region
- 🇪🇺 EU
- Active substance
- diroximel fumarate
- Company
- Biogen Netherlands B.V.
- Status
- Authorised
- Therapeutic area
- Multiple Sclerosis, Relapsing-Remitting
- CHMP opinion
- Thu 16 Sep 2021
- EU approval
- Mon 15 Nov 2021
- Application
- EMEA/H/C/005437
- ATC
- L04AX07
- Official record
- www.ema.europa.eu
Indication
Vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see Section 5.1 for important information on the populations for which efficacy has been established).
Regulatory milestones
No milestones recorded in the last year.
Follow Vumerity
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.